Intelence is a medicine for treating human immunodeficiency virus type 1 (HIV-1) in adults and children from 2 years of age. HIV-1 causes acquired immune deficiency syndrome (AIDS). Intelence is only used in patients who have been treated for their HIV infection before and it must be used together with other HIV medicines that include a ‘boosted protease inhibitor’. It contains the active substance etravirine.
Therapeutic Indication
### Therapeutic indication Intelence, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human-immunodeficiency-virus-type-1 (HIV-1) infection in antiretroviral-treatment-experienced adult patients and in antiretroviral-treatment-experienced paediatric patients from six years of age. This indication is based on week-48 analyses from two phase-III trials in highly pretreated patients where Intelence was investigated in combination with an optimised background regimen (OBR) which included darunavir/ritonavir. The indication in paediatric patients is based on 48-week analyses of a single-arm, phase-II trial in antiretroviral-treatment-experienced paediatric patients.
Therapeutic Area (MeSH)
N/AATC Code
J05AG04
ATC Item
etravirine
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Etravirine | N/A | 依曲韦林 |
EMA Name
Intelence
Medicine Name
Intelence
Aliases
N/ANo risk management plan link.
